ZYDUS LIFESCIENCES LIMITED
- Country
- 🇮🇳India
- Ownership
- -
- Established
- 1952-01-01
- Employees
- -
- Market Cap
- $13.6B
- Website
- http://cadilapharma.com
Clinical Trials
47
Trial Phases
5 Phases
Drug Approvals
313
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 32
- Next
Clinical Trials
Distribution across different clinical trial phases (47 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: Arm1Drug: Arm 2
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT06398808
- Locations
- 🇮🇳
ICON Hospital, Ahmedabad, Gujarat, India
Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: ZYIL1 capsules 25 mg and 50 mg PlaceboDrug: ZYIL1 capsules 50 mg and 25 mg PlaceboDrug: ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mgDrug: Matching placebo 25 mg and Matching placebo 50 mg
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 24
- Registration Number
- NCT05981040
- Locations
- 🇮🇳
Zydus Hospitals & Healthcare Research, Ahmedabad, Gujarat, India
🇮🇳Rhythm heart institute, Vadodara, Gujarat, India
🇮🇳BrainS Super Speciality Hospital, Bengaluru, Karnataka, India
A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers
- Conditions
- Falciparum MalariaAsymptomatic ConditionUncomplicated Malaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 36
- Registration Number
- NCT05911828
- Locations
- 🇬🇦
Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon
A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities
- Conditions
- NAFLDType 2 DiabetesObesityDyslipidemiasMetabolic Syndrome
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 1500
- Registration Number
- NCT05872269
- Locations
- 🇮🇳
Gastroplus Digestive Disease Centre, Ahmedabad, India
🇮🇳Mission GastroHospital, Ahmedabad, India
🇮🇳Artemis Hospital, Gurgaon, India
A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)
- Conditions
- Chronic Kidney DiseasesAnemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Zydus Lifesciences Limited
- Target Recruit Count
- 1004
- Registration Number
- NCT05515367
- Locations
- 🇮🇳
Indira Gandhi Institute of Medical Sciences, Sheikhpura, Bihar, India
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Sun Pharma Names Kirti Ganorkar as Managing Director in Major Leadership Transition
Kirti Ganorkar, a 29-year Sun Pharma veteran, will become Managing Director on September 1, 2025, succeeding founder Dilip Shanghvi who transitions to Executive Chairman.
Zydus Lifesciences Secures Exclusive Rights to Agenus' BOT/BAL Cancer Immunotherapy for India and Sri Lanka
Zydus Lifesciences has signed an exclusive licensing agreement with US-based Agenus Inc to commercialize the investigational cancer therapy combination of Botensilimab (BOT) and Balstilimab (BAL) in India and Sri Lanka.
Sickle Cell Disease Pipeline Shows Robust Growth with 60+ Therapies in Development Across Multiple Clinical Phases
DelveInsight's 2025 assessment reveals a robust sickle cell disease pipeline with 55+ companies developing 60+ therapeutic candidates across various clinical development stages.
Zydus MedTech Partners with Braile Biomedica to Expand TAVI Technology Across Europe and India
Zydus MedTech has formed a strategic partnership with Brazil-based Braile Biomedica to exclusively commercialize Transcatheter Aortic Valve Implantation (TAVI) technology in Europe, India, and select markets.
NULIBRY Shows Significant Survival Benefits in Ultra-Rare MoCD Type A: Landmark Clinical Evidence Published
Sentynl Therapeutics has published the first comprehensive clinical evidence for NULIBRY (fosdenopterin), showing statistically significant survival benefits in patients with Molybdenum Cofactor Deficiency Type A compared to untreated patients.
Real-World Studies Confirm Bevacizumab Biosimilars Deliver Cost Savings and Equivalent Clinical Outcomes in Metastatic Colorectal Cancer
A Canadian population-based study found bevacizumab biosimilars Mvasi and Zirabev provided $6,379 CAD in annual cost savings per patient compared to originator Avastin while maintaining equivalent survival outcomes in metastatic colorectal cancer.
Zydus Lifesciences Secures USFDA Approval for Generic Ketoconazole Shampoo
Zydus Lifesciences has received final USFDA approval to manufacture Ketoconazole Shampoo 2%, a generic equivalent of Nizoral Shampoo used to treat dandruff and fungal skin infections.
Zydus Launches ANVIMO: Game-Changing CMV Prevention Drug for Transplant Patients at 91% Lower Cost
Zydus Lifesciences introduces ANVIMO (letermovir) in India, offering a breakthrough treatment for preventing Cytomegalovirus infection in stem cell and kidney transplant patients.
Zydus Lifesciences' Topical Manufacturing Facility Achieves Perfect FDA Inspection Amid Strong Q3 Performance
Zydus Lifesciences' Ahmedabad-based topical manufacturing facility successfully passed USFDA inspection with zero observations during a routine surveillance conducted February 10-14, 2025.
Zydus' Usnoflast Receives FDA Orphan Drug Designation and Phase 2b Trial Approval for ALS Treatment
The FDA has granted Orphan Drug Designation to Zydus' Usnoflast for treating amyotrophic lateral sclerosis (ALS), a rare neurodegenerative disease.